The mitochondria power the cell. We? We power your mitochondrial research. SS-31 is a complex compound, and even minor impurities can prevent proper binding to cardiolipin. CellPeptides is the EU-based research and scientific company researchers can count on when they need pharmaceutical-grade peptides for studies that might just change everything.<\/p>\n
Our SS-31 is synthesized to match the exact D-Arg-Dmt-Lys-Phe sequence Dr Szeto pioneered. It\u2019s:<\/p>\n
Need research support? CellPeptides has an always-on customer service team that can answer more than questions about ordering (although we definitely do that, too). We\u2019ll give you guidance based on your study design.<\/p>\n
An extra plus? Peptide quality is not negotiable, so payment methods are less important in the grand scheme, but we do take crypto as well as accepting major credit cards and bank transfers.<\/p>\n
Pretty elegantly.<\/p>\n
The mitochondria make roughly 90 percent of all the energy the body needs to keep going, namely in the form of ATP. That generation takes place along the inner mitochondrial membrane, within cristae. It\u2019s also where you find cardiolipin, which does maintenance for cristae and organizes the proteins necessary for the electron transport chain \u2014 needed to make ATP.<\/p>\n
The whole process works very nicely and effectively. Until, that is, age or disease disrupt it. Reactive oxygen species oxidize cardiolipin. The proteins the electron transport chain needs get left behind. The entire chain starts \u201cleaking\u201d and becomes chaotic and less effective. ATP goes down. More reactive oxygen species show up. The mitochondrial degradation process continues.<\/p>\n
SS-31 can go into any cell, but it\u2019s naturally attracted to the inner mitochondrial membranes \u2014 because of its positive charge. Once it arrives on location, SS-31 binds to cardiolipin, stops it from being oxidized, restores cristae, reduces electron transport chain degradation, and gets ATP production up for better energy usage.<\/p>\n
Forget symptom management. SS-31 goes straight for the root cause. That\u2019s impressive \u2014 and it comes with fascinating research potential.<\/p>\n
SS-31, its investigational drug name, is undoubtedly among the most exciting peptides currently being researched. Dr Hazel Szeto discovered it in the early 2000s while researching peptides that target opioid receptors \u2014 with fascinating but entirely unexpected effects.<\/p>\n
Because SS-31 selectively zooms in on the inner mitochondrial membrane, where it protects cardiolipin, the research potential is massive. Early trials have looked at rare mitochondrial diseases like Barth syndrome. (They were always going to be first.) The potential goes beyond that, however. Far beyond that. Researchers are now using SS-31 to investigate nearly every area of age-related decline.<\/p>\n
Geroscience studies are in their early stages, where progress has been made in animal models, but that doesn\u2019t make it any less exciting. The study of cellular aging (and the potential to slow it down, or even turn back the clock) is unquestionably the area that has the most widespread future application potential.<\/p>\n
SS-31 was shown to reverse<\/em> the signs of aging in mice and rats \u2014 better physical and muscle performance, sharper cognition, and better body weight maintenance, along with healthier cardiac and renal tissues. Researchers have demonstrated \u201cpro-longevity shifts\u201d in gene expression and<\/em> anti-inflammatory potential. [1<\/a>, 2<\/a>] Impressive? It\u2019s hard to say otherwise.<\/p>\n Mitochondrial dysfunction plays a huge part in the complex conditions that lead to neurodegenerative diseases like Alzheimer\u2019s. Research into this area remains in the preclinical phase, but has already been promising \u2014 SS-31 can cross the blood-brain barrier. It slashes oxidative stress, it improves synaptic firing, and it protects neurons. So far, Alzheimer\u2019s, Parkinson\u2019s, and ALS have been the main areas of research. [3<\/a>, 4<\/a>]\n This is where the most likely near-term clinical uses for SS-31 are found, and where human trials have already begun. SS-31 improves both cardiac output and exercise tolerance in people who have Barth syndrome. This rare mitochondrial disorder impacts cardiolipin, and there were no viable treatment directions before research into SS-31 as a potential future option started. [5<\/a>, 6<\/a>]\n The heart demands a lot of energy \u2014 which can strain the mitochondria. It\u2019s no surprise that research has investigated how SS-31 might be able to help with heart failure and other cardiovascular diseases. So far, it\u2019s shown that SS-31 has a strong cardioprotective effect. It\u2019s especially helpful in cases of ischemia-reperfusion injury, damage associated with blood flow restoration after a heart attack. [7<\/a>] Restoring mitochondrial function = slowing cell death and improving recovery rates.<\/p>\n SS-31 has been similarly promising in the area of kidney disease (both acute and chronic). The mechanism at play here is reducing oxidative stress and fighting inflammation. The kidneys are packed with mitochondria. [8<\/a>]\n Macular degeneration robs millions of their eyesight, slowly but surely \u2014 and it has no reliable treatment at the moment. Early research has made SS-31 an exciting area of study. So far, SS-31 was shown to protect photoreceptors and retinal pigment epithelial cells from degradation caused by mitochondrial dysfunction. [9<\/a>] What\u2019s more, research into the potential of SS-31 in treating glaucoma is also in full swing [10<\/a>].<\/p>\n You\u2019ve seen a glimpse of the current study directions, but it\u2019s still early days for SS-31. The potential is there \u2014 ready for any researcher excited to make breakthroughs. Those breakthroughs range from bringing potential treatment options to people with ultra-rare mitochondrial diseases to the study of aging itself.<\/p>\n SS-31 is particularly relevant for researchers investigating:<\/p>\n The mitochondria power everything. And everyone. The research applications of SS-31 are wide open.<\/p>\n Existing research protocols have led to a standard dosing protocol of 1 mg to 5 mg per day \u2014 or 0.5 to 5.0 mg per kg based on the model\u2019s weight. Most study designs begin with a lower dose to observe how the model responds and titrate up from there. Some designs trial shorter or even single doses in response to acute situations.<\/p>\n Dosing is, of course, dependent on the model and research goal. Investigators should consult the existing literature.<\/p>\n The side effect profile is favorable overall, including in phase 1 and 2 human trials with long-term use. Administration is subcutaneous or intraperitoneal, and SS-31 has to be reconstituted from the lyophilized form. This is done with bacteriostatic water (never tap or distilled) \u2014 add 2 mL to a 10 mg vial of SS-31. Reconstituted SS-31 can be stored at temperatures between 2 and 8\u00b0C for multi-dose applications, to be used within 30-60 days and discarded when cloudy.<\/p>\n For new researchers, we encourage to use our comprehensive peptide calculator<\/a> – which shows how much peptide you should draw in order to achieve the desired dose based on how much BAC water you added.<\/p>\n What does SS-31 do for the kidneys?<\/strong><\/p>\n SS-31, research suggests, protects kidney function by improving mitochondrial health in the energy-intensive tubules. Studies in chronic and acute models have demonstrated lower oxidative stress, less inflammation, and reduced tubular cell death.<\/p>\n Does SS-31 have any potential weight loss applications?<\/strong><\/p>\n This peptide mainly improves cellular energy production. It\u2019s not a weight loss peptide. Mitochondrial function is relevant throughout the body, however, and SS-31 might improve metabolic health and indirectly support weight loss. To be determined by future studies.<\/p>\n What are the side effects of SS-31?<\/strong><\/p>\n This peptide has an exceptionally good safety profile comparable to placebo. Redness is the main possible side effect.<\/p>\n What are the beneficial effects of SS-31 on cardiac mitochondrial dysfunction in Tafazzin knockdown mice?<\/strong><\/p>\n This question is about a Barth syndrome model \u2014 TAZ-KD mice. SS-31 successfully restored heart function, improved mitochondrial morphology (prevented abnormal cristae shape), boosted ATP, and reduced reactive oxygen species. This research was absolutely integral to advancing SS-31 in clinical trials!<\/p>\n SS-31<\/strong> este o peptid\u0103 sintetic\u0103 care are un impact major asupra mitocondriilor celulare. Aceast\u0103 peptid\u0103 permeabil\u0103 la celule, descoperit\u0103 aproape din \u00eent\u00e2mplare de dr. Hazel Szeto \u0219i dr. Peter Schiller, \u021binte\u0219te membrana mitocondrial\u0103 intern\u0103 \u0219i se leag\u0103 selectiv de cardiolipin\u0103<\/strong>. \u00cen timp ce organismul produce \u0219i alte peptide derivate mitocondriale, aceasta este unic\u0103. Un exemplu de m\u0103iestrie asupra naturii. SS-31 intervine pentru a preveni oxidarea cardiolipinei, a reduce daunele provocate de radicalii liberi \u0219i a stimula produc\u021bia de ATP (energie) \u00een mitocondrii.<\/p>\n Semnele vizibile ale \u00eemb\u0103tr\u00e2nirii \u2014 ridurile din ce \u00een ce mai ad\u00e2nci, articula\u021biile rigide, oboseala \u2014 sunt doar simptomele de la suprafa\u021b\u0103 ale unei probleme mult mai profunde. Deteriorarea mitocondrial\u0103.<\/p>\n \u00cen interiorul fiec\u0103rei celule, aceste \u201ccentrale electrice\u201d \u00ee\u0219i pierd treptat suflul. Cardiolipina, \u201cadezivul\u201d fosfolipidic care \u021bine laolalt\u0103 membrana mitocondrial\u0103 \u0219i capacitatea ei de a produce energie, este oxidat\u0103 de radicalii liberi. Produc\u021bia de energie (ATP) scade brusc, speciile reactive de oxigen inund\u0103 celula, iar cascad\u0103 nedorit\u0103 a \u00eemb\u0103tr\u00e2nirii celulare \u00ee\u0219i urmeaz\u0103 cursul.<\/p>\n Aplica\u021biile de cercetare? \u00cencep cu bolile mitocondriale rare \u0219i insuficient cercetate, continu\u0103 cu s\u0103n\u0103tatea cardiovascular\u0103, bolile renale, bolile neurodegenerative \u0219i bolile oculare, \u0219i \u00een cele din urm\u0103 ajung la punctul lor final logic. \u00cens\u0103\u0219i \u00eemb\u0103tr\u00e2nirea.<\/p>","protected":false},"featured_media":1021,"template":"","meta":{"_acf_changed":false,"ub_ctt_via":""},"product_brand":[],"product_cat":[52,46,45,54],"product_tag":[],"class_list":["post-872","product","type-product","status-publish","has-post-thumbnail","product_cat-anti-inflammatory-response-research-peptides","product_cat-peptides-for-longevity-research","product_cat-peptides-for-fat-metabolism-research","product_cat-peptides-for-tissue-healing-research","first","instock","shipping-taxable","purchasable","product-type-simple"],"acf":[],"yoast_head":"\nHope for Neurodegenerative Diseases in Early Trials<\/h3>\n
SS-31 as a Potential Treatment for Mitochondrial Diseases<\/h3>\n
SS-31 for Heart Failure, Cardiovascular Disease, and Kidney Disease<\/h3>\n
Age-Related Macular Degeneration and Other Eye Diseases<\/h3>\n
Who Might Consider SS-31?<\/h2>\n
\n
Common Research Dosing Protocols for SS-31 In-vitro Setting<\/h2>\n
FAQ<\/h2>\n
Scientific References<\/em><\/h3>\n
\n